請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/55385
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳垣崇 | |
dc.contributor.author | Chia-Hsien Lin | en |
dc.contributor.author | 林嘉嫻 | zh_TW |
dc.date.accessioned | 2021-06-16T03:59:41Z | - |
dc.date.available | 2015-03-12 | |
dc.date.copyright | 2015-03-12 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-11-20 | |
dc.identifier.citation | 1. Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, Deyo RA, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008; 58:26-35.
2. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006; 58:87-114. 3. Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010; 6:30-8. 4. Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol 2002; 14:281-6. 5. Fam AG, Dunne SM, Iazzetta J, Paton TW. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum 2001; 44:231-8. 6. Rundles RW. The development of allopurinol. Arch Intern Med 1985; 145:1492-503. 7. Excess of amphicillin rashes associated with allopurinol or hyperuricemia. A report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. N Engl J Med 1972; 286:505-7. 8. Aubock J, Fritsch P. Asymptomatic hyperuricaemia and allopurinol induced toxic epidermal necrolysis. Br Med J (Clin Res Ed) 1985; 290:1969-70. 9. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993; 27:337-43. 10. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102:4134-9. 11. Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58:25-32. 12. Tohkin M, Ishiguro A, Kaniwa N, Saito Y, Kurose K, Hasegawa R. Prediction of severe adverse drug reactions using pharmacogenetic biomarkers. Drug Metab Pharmacokinet 2010; 25:122-33. 13. Tohkin M, Kaniwa N, Saito Y, Sugiyama E, Kurose K, Nishikawa J, et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J 2013; 13:60-9. 14. Roujeau J-C, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis. New England Journal of Medicine 1995; 333:1600-8. 15. Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol 2011; 127:S60-6. 16. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128:35-44. 17. Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC, et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 2011; 364:1126-33. 18. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005; 209:123-9. 19. Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nat Rev Genet 2003; 4:937-47. 20. Evans WE, McLeod HL. Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med 2003; 348:538-49. 21. Mondino BJ, Brown SI, Biglan AW. HLA antigens in Stevens-Johnson syndrome with ocular involvement. Arch Ophthalmol 1982; 100:1453-4. 22. Power WJ, Saidman SL, Zhang DS, Vamvakas EC, Merayo-Lloves JM, Kaufman AH, et al. HLA typing in patients with ocular manifestations of Stevens-Johnson syndrome. Ophthalmology 1996; 103:1406-9. 23. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428:486. 24. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359:727-32. 25. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009; 41:816-9. 26. Martin AM, Nolan D, James I, Cameron P, Keller J, Moore C, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 2005; 19:97-9. 27. Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, et al. HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2008; 9:1617-22. 28. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, et al. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18:99-107. 29. Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009; 19:704-9. 30. Kang HR, Jee YK, Kim YS, Lee CH, Jung JW, Kim SH, et al. Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans. Pharmacogenet Genomics 2011; 21:303-7. 31. Jung JW, Song WJ, Kim YS, Joo KW, Lee KW, Kim SH, et al. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant 2011; 26:3567-72. 32. Yun J, Mattsson J, Schnyder K, Fontana S, Largiader CR, Pichler WJ, et al. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response. Clin Exp Allergy 2013; 43:1246-55. 33. Yun J, Marcaida MJ, Eriksson KK, Jamin H, Fontana S, Pichler WJ, et al. Oxypurinol Directly and Immediately Activates the Drug-Specific T Cells via the Preferential Use of HLA-B*58:01. J Immunol 2014. 34. Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P, et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114:1209-15. 35. Naisbitt DJ, Farrell J, Wong G, Depta JP, Dodd CC, Hopkins JE, et al. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 2003; 111:1393-403. 36. Wu Y, Sanderson JP, Farrell J, Drummond NS, Hanson A, Bowkett E, et al. Activation of T cells by carbamazepine and carbamazepine metabolites. J Allergy Clin Immunol 2006; 118:233-41. 37. Gueant-Rodriguez RM, Gueant JL, Viola M, Tramoy D, Gaeta F, Romano A. Association of tumor necrosis factor-alpha -308G>A polymorphism with IgE-mediated allergy to betalactams in an Italian population. Pharmacogenomics J 2008; 8:162-8. 38. Vyas JM, Van der Veen AG, Ploegh HL. The known unknowns of antigen processing and presentation. Nat Rev Immunol 2008; 8:607-18. 39. Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr Opin Allergy Clin Immunol 2002; 2:301-5. 40. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139:683-93. 41. Griem P, Wulferink M, Sachs B, Gonzalez JB, Gleichmann E. Allergic and autoimmune reactions to xenobiotics: how do they arise? Immunol Today 1998; 19:133-41. 42. Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, et al. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol 2003; 63:732-41. 43. Naisbitt DJ, Gordon SF, Pirmohamed M, Park BK. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf 2000; 23:483-507. 44. Park BK, Pirmohamed M, Kitteringham NR. Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem Res Toxicol 1998; 11:969-88. 45. Nishimura MI, Avichezer D, Custer MC, Lee CS, Chen C, Parkhurst MR, et al. MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte. Cancer Res 1999; 59:6230-8. 46. Willemsen R, Ronteltap C, Heuveling M, Debets R, Bolhuis R. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha. Gene Ther 2005; 12:140-6. 47. Boyle LH, Goodall JC, Gaston JS. The recognition of abnormal forms of HLA-B27 by CD4+ T cells. Curr Mol Med 2004; 4:51-8. 48. Roddis M, Carter RW, Sun MY, Weissensteiner T, McMichael AJ, Bowness P, et al. Fully functional HLA B27-restricted CD4+ as well as CD8+ T cell responses in TCR transgenic mice. J Immunol 2004; 172:155-61. 49. Yang Y, Wilson JM. Clearance of adenovirus-infected hepatocytes by MHC class I-restricted CD4+ CTLs in vivo. J Immunol 1995; 155:2564-70. 50. Farrell J, Lichtenfels M, Sullivan A, Elliott EC, Alfirevic A, Stachulski AV, et al. Activation of carbamazepine-responsive T-cell clones with metabolically inert halogenated derivatives. J Allergy Clin Immunol 2013; 132:493-5. 51. Jordheim LP, Durantel D, Zoulim F, Dumontet C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov 2013; 12:447-64. 52. Yun J, Marcaida MJ, Eriksson KK, Jamin H, Fontana S, Pichler WJ, et al. Oxypurinol directly and immediately activates the drug-specific T cells via the preferential use of HLA-B*58:01. J Immunol 2014; 192:2984-93. 53. Lockard O, Jr., Harmon C, Nolph K, Irvin W. Allergic reaction to allopurinol with cross-reactivity to oxypurinol. Ann Intern Med 1976; 85:333-5. 54. Mauri-Hellweg D, Zanni M, Frei E, Bettens F, Brander C, Mauri D, et al. Cross-reactivity of T cell lines and clones to beta-lactam antibiotics. J Immunol 1996; 157:1071-9. 55. Zawodniak A, Lochmatter P, Beeler A, Pichler WJ. Cross-reactivity in drug hypersensitivity reactions to sulfasalazine and sulfamethoxazole. Int Arch Allergy Immunol 2010; 153:152-6. 56. Wei CY, Chung WH, Huang HW, Chen YT, Hung SI. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. J Allergy Clin Immunol 2012; 129:1562-9 e5. 57. Ko TM, Chung WH, Wei CY, Shih HY, Chen JK, Lin CH, et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol 2011; 128:1266-76 e11. 58. Schnyder B, Frutig K, Mauri-Hellweg D, Limat A, Yawalkar N, Pichler WJ. T-cell-mediated cytotoxicity against keratinocytes in sulfamethoxazol-induced skin reaction. Clin Exp Allergy 1998; 28:1412-7. 59. Wu Y, Farrell J, Pirmohamed M, Park BK, Naisbitt DJ. Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity. J Allergy Clin Immunol 2007; 119:973-81. 60. Cavani A, Mei D, Guerra E, Corinti S, Giani M, Pirrotta L, et al. Patients with allergic contact dermatitis to nickel and nonallergic individuals display different nickel-specific T cell responses. Evidence for the presence of effector CD8+ and regulatory CD4+ T cells. J Invest Dermatol 1998; 111:621-8. 61. Zhang Y, Mei H, Wang Q, Xie J, Lv J, Pan X, et al. Peptide binding specificities of HLA-B*5701 and B*5801. Sci China Life Sci 2012; 55:818-25. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/55385 | - |
dc.description.abstract | 別嘌呤醇 (Allopurinol)被用來治療痛風已經持續了近半個世紀,且到現今還是最常用的藥物之ㄧ,但是在某些服用這個藥物的病人身上會產生嚴重性皮膚不良反應 (SCAR),包括了過敏症候群 (Hypersensitivity Syndrome)、史蒂文生氏-強生症候群 (Steven-Johnson Syndrome)與毒性表皮壞死溶解症 (Toxic Epidermal Necrolysis)。在我們先前的研究團隊中發現在這些別嘌呤醇藥物過敏病人的體內帶有人類白血球抗原B型58:01(HLA-B*58:01)這一個共同的基因標記,但是別嘌呤醇所引起嚴重皮膚過敏反應的致病機轉仍未釐清。為了探討別嘌呤醇所引起過敏反應的致病機轉,我們研究別嘌呤醇和它的代謝物氧化嘌呤醇(Oxypurinol)與人類白血球抗原B型58:01分子之間的交互作用。本論文共分析14個別嘌呤醇所引起過敏反應的病人,並研究這些病人的周邊血液單核細胞對別嘌呤醇和代謝物氧化嘌呤醇的免疫反應。我們用病人周邊血液單核細胞進行體外細胞培養,分析免疫細胞分型(cell phenotype),並且使用檢測細胞增生(cell proliferation assay)、細胞毒性分析(T cell cytotoxic assay) 、表面電漿共振技術(surface plasmon resonance, SPR)和點突變(site-directed mutagenesis)等方法,來探討藥物和人類白血球抗原B型58:01分子之間的交互作用。我們使用這個系統將14個別嘌呤醇過敏病人血液中藥物專一性的細胞活化出來。這些藥物專一性的細胞同時對別嘌呤醇和氧化嘌呤醇有交叉反應(cross-reactivity),並且活化出CD4+ 和CD8+的免疫細胞。這些活化後的免疫細胞對帶有人類白血球抗原B型58:01的抗原呈現細胞(Antigen-presenting cells)有專一性。這些免疫細胞的增生能力不會受到抗原呈現細胞固定(pre-fixation)的影響,因次我們認為可能在活化免疫細胞過程中,藥物的呈現不需要經過抗原呈現細胞的加工處理。利用表面電漿共振技術來分析人類白血球抗原B型58:01和藥物別嘌呤醇和氧化嘌呤醇之間的結合能力。在人類白血球抗原B型58:01中胺基酸Arg97是和藥物結合的重要位置。總而言之,這一篇研究探討人類白血球抗原(HLA)參與在別嘌呤醇或氧化嘌呤醇之間的交互作用,證實人類白血球抗原B型58:01引起嚴重皮膚過敏反應的免疫分子之間的致病機轉。 | zh_TW |
dc.description.abstract | Allopurinol is a commonly prescribed drug for symptomatic hyperuricemia and its complication, gout. The major limitation of allopurinol is that it is a frequent cause of severe cutaneous adverse reactions (SCARs), including hypersensitivity syndrome (HSS), Stevens–Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). Our previous study showed that susceptibility to these life-threatening reactions induced by allopurinol is genetically determined and is strongly associated with HLA-B*58:01. The underlying mechanism remains unclear, however. To investigate the pathogenesis of allopurinol-SCAR, we aimed to study the interactions between the allopurinol or oxypurinol and HLA-B*58:01 molecules. We enrolled 14 patients with allopurinol-induced SCAR and studied the response of their cultured peripheral blood mononuclear cells (PBMCs) to allopurinol or oxypurinol. In vitro-expanded T lymphocytes from the patients were evaluated for cell phenotype, and their interaction with HLA-B*58:01 and the drug analyzed, based on proliferation ability, cytotoxic T lymphocyte (CTL) response, surface plasmon resonance (SPR) and site-directed mutagenesis. T cell lines from 14 allopurinol-SCAR patients in the presence of allopurinol or oxypurinol were generated. These T-cell lines (TCLs) displayed cross-reactivity between allopurinol and oxypurinol, and both CD4+ and CD8+ T cells were present. The expanded T Cells were activated and restricted by antigen-presenting cells expressing HLA-B*58:01 in the presence of drug. The proliferation of T cells was not altered by the pre-fixation of antigen presenting cells (APC), suggesting the involvement of an antigen-processing-independent pathway. Using SPR analysis, HLA-B*58:01 was shown to exhibit specific binding affinity to allopurinol and oxypurinol. Arg97 between the E and C pocket of HLA-B*58:01 is a key residue involved in drug presentation. This study demonstrates an interaction between HLA and allopurinol or oxypurinol, and provides a molecular-level understanding of allopurinol-induced SCARs associated with HLA-B*58:01. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T03:59:41Z (GMT). No. of bitstreams: 1 ntu-103-D97445005-1.pdf: 4807383 bytes, checksum: e3464853703bce54818d8320bd48a237 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | Signature Page ---------------------------------------------- I
Thesis Approval Form ------------------------------------- II Acknowledgement ------------------------------------------ III Table of Contents ------------------------------------------- i List of Figures ----------------------------------------------- iv List of Tables ------------------------------------------------ v List of Abbreviation --------------------------------------- vi Abstract ------------------------------------------------------ vii Chinese Abstract中文摘要 ------------------------------ ix Chapter 1. Introduction 1.1Allopruinol------------------------------------------1 1.2 Adverse drug reactions (ADRs) -------------------------------2 1.2.1 Clinical features --------------------------------------------2 1.3 Pharmacogenesis studies on ADRs -----------------------------------------3 1.3.1 Strong association between HLA-B*58:01 and allopurinol-induced SCARs--4 1.4 The role of HLA in drug hypersensitivity----------------------------------5 1.4.1 Human Leukocyte Antigen (HLA) -------------------------------------6 1.4.2 Antigen presentation by HLA-----------------------------------------7 1.4.3 Drug presentation mechanisms: the hapten/ prohapten concept----------------8 1.4.4 Drug presentation mechanisms: the p-i concept-----------------------9 1.4.5 How T cells recognize such a small molecules like drug-----------------------9 1.5 Hypothesis------------------------------------------------------10 1.6 Specific aim----------------------------------------------------11 Chapter 2. Materials and Methods 2.1 Clinical Samples-----------------------------------------------12 2.2 HLA genotyping-----------------------------------------------12 2.3 Culture medium and reagents--------------------------------13 2.4 Constructs-------------------------------------------------------13 2.5 In vitro stimulation of drug-specific T cells------------------------------15 2.6 Flow cytometry-------------------------------------------------15 2.7 Determination of oxypurinol-specific cytotoxic activity in vitro (T cell cytotoxic assay) ---------------------------------------16 2.8 Investigation of drug-specific T-cell activation (T cell proliferation assays) -----16 2.9 Surface Plasmon resonance (SPR) measurement and analyses----------------------17 2.10 High-performance liquid chromatography (HPLC) -------------------18 Chapter 3. Results 3.1 Cross-reactivity of T cell lines generated from allopurinol-SCAR patients-------19 3.2 Allopurinol is stable in the cell culture system--------------------------20 3.3 Cytotoxicity of drug-specific T cells and the release of granulysin----------------21 3.4 T cell types in oxypurinol-enriched TCLs-------------------------------21 3.5 Drug-specific T cells are activated and restricted by antigen-presenting cells expressing HLA-B*58:01----------------------------------------22 3.6 HLA-B*58:01 molecules directly present oxypurinol-----------------24 3.7 HLA-B*58:01 molecules directly present oxypurinol-----------------24 3.8 Key residue in HLA-B*58:01 for oxypurinol presentation -------------------------25 Chapter 4. Discussion--------------------------------------------27 Chapter 5. References -------------------------------------------32 Chapter 6. Figures------------------------------------------------39 Chapter 7. Tables-------------------------------------------------52 Chapter 8. Appendixes ------------------------------------------55 List of Figures Figure 1. Drug-specific T cells in patients with allopurinol-induced SCARs are activated in concentration–dependent manner.------------------------------39 Figure 2. Cross-reactivity of T cells from HLA-B*58:01-positive allopurinol-SCAR patients. ----------------------------------------------40 Figure 3. Validation that allopurinol is not converted to oxypruinol in cell culture medium by high-performance liquid chromatography (HPLC). -----------------------42 Figure 4. Cytotoxicity of oxypurinol-specific T cells revealed by the release of granulysin. -------------------------------------------44 Figure 5. Drug-specific CD4+ and CD8+ T cells are activated and restricted by antigen-presenting cells expressing HLA-B*58:01. -----------------------46 Figure 6. HLA-B*58:01-dependent activation of oxypurinol-specific T cell proliferation in patients with allopurinol-induced SCARs. ---------------48 Figure 7. Molecular interaction of HLA-B*58:01 molecule and drugs. --------------49 Figure 8. The key residues of oxypurinol recognition map to the HLA-B*58:01 cleft. ----------------------------------------------------------51 List of Tables Table I. Clinical details and T cell types of patients with allopurinol-induced adverse drug reaction -------------------------------------------------------52 Table II. Recent HLA associations with serious adverse drug reactions--------------53 Table III. Cross-reactivity of allopurinol-generated TCLs toward allopruinol and oxypurinol -------------------------------------------54 Table IV. Cross-reactivity of oxypurinol-generated TCLs toward allopruinol and oxypurinol -------------------------------------------54 | |
dc.language.iso | en | |
dc.title | 探討別嘌呤醇引起藥物過敏反應中人類白血球抗原B型58:01與藥物專一性T細胞之間的免疫和分子機制 | zh_TW |
dc.title | Immunological basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B*58:01-restricted activation of drug-specific T cells and molecular interaction | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 鄔哲源,嚴仲陽,廖有地,顧家綺,繆希椿 | |
dc.subject.keyword | 別嘌呤醇,氧化嘌呤醇,人類白血球抗原B型58:01,嚴重性皮膚不良反應,周邊血液單核細胞, | zh_TW |
dc.subject.keyword | Allopurinol,Oxypurinol,HLA-B,58:01,severe cutaneous adverse reaction,peripheral blood mononuclear cells, | en |
dc.relation.page | 54 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2014-11-21 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 4.69 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。